This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Jul 20;13(8):466.

doi: 10.1038/nrclinonc.2016.114.

Immunotherapy: High promise for pembrolizumab in HL

Lisa Hutchinson

PMID: 27435267
DOI: 10.1038/nrclinonc.2016.114

Comment

Immunotherapy: High promise for pembrolizumab in HL

Lisa Hutchinson. Nat Rev Clin Oncol. 2016.

. 2016 Jul 20;13(8):466.

doi: 10.1038/nrclinonc.2016.114.

Author

Lisa Hutchinson

PMID: 27435267
DOI: 10.1038/nrclinonc.2016.114

No abstract available

PubMed Disclaimer

Comment on

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Armand P, et al. J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467. J Clin Oncol. 2016. PMID: 27354476 Free PMC article. Clinical Trial.

References

1. J Clin Oncol. 2016 Jun 27;:null - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations